Log in
Enquire now
‌

Natural History Study of Batten Disease

OverviewStructured DataIssuesContributors

Contents

clinicaltrials.gov/study/NCT04644549
Is a
‌
Clinical study
0

Clinical Study attributes

NCT Number
NCT046445490
Health Conditions in Trial
‌
Batten disease
0
Trial Recruitment Size
100
Trial Sponsor
Amicus Therapeutics
Amicus Therapeutics
0
Clinical Trial Start Date
April 27, 2021
0
Primary Completion Date
March 11, 2022
0
Study Completion Date
March 11, 2022
0
Clinical Trial Study Type
Observational0
Observational Clinical Trial Type
Cohort0
Observational Study Perspective
Other0
Participating Facility
University of Rochester Medical Center
University of Rochester Medical Center
0
Official Name
Natural History Study of Batten Disease0
Last Updated
April 11, 2022
0
Study summary

This is a multicenter, international, study to assess the natural history data from people with Batten disease by collecting both retrospective and prospective information about the motor, behavioral and functional capabilities of patients. The study initially has 2 cohorts. Cohort 1 (n ≈ 75) includes subjects with CLN6 Batten disease. Cohort 2 (n ≈ 120) includes subjects with juvenile CLN3 Batten disease. Additional cohorts for other Batten disease subtypes may be added in the future.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Natural History Study of Batten Disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.